Here we describe the use of CAR-CD19 T cells that secrete CD19 bridging proteins as a highly effective therapeutic approach to targeting hematologic cancers and solid tumors. The gene discussed is CD19; the disease is hematopoietic and lymphoid cell neoplasm.